Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
29 Agosto 2023 - 9:00AM
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company
developing a new generation of oral integrin therapies for the
treatment of serious chronic diseases, today announced that Marc
Schegerin, MD, COO & CFO, will participate in a fireside chat
at the Wells Fargo Healthcare Conference on Wednesday, September
6th at 8:00 AM ET.
A live webcast of the event will be available on
the Investor section of Morphic’s website at www.morphictx.com. An
archived replay will be available on the company’s website
following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical
company developing a new generation of oral integrin therapies for
the treatment of serious chronic diseases, including autoimmune,
cardiovascular, and metabolic diseases, fibrosis, and cancer. In
collaboration with Schrödinger, Morphic is advancing its
pipeline and discovery activities using its proprietary MInT
technology platform which leverages the Company’s unique
understanding of integrin structure and biology. For more
information, visit www.morphictx.com.
ContactsMorphic TherapeuticChris
Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024